IP Verse

Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer - EP3725810

The patent EP3725810 was granted to Astellas Pharma on Jul 6, 2022. The application was originally filed on May 21, 2013 under application number EP20163993A. The patent is currently recorded with a legal status of "Revoked".

EP3725810

ASTELLAS PHARMA
Application Number
EP20163993A
Filing Date
May 21, 2013
Status
Revoked
Jan 3, 2025
Grant Date
Jul 6, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BAYERApr 6, 2023BIP PATENTSADMISSIBLE
MAIWALDApr 6, 2023MAIWALDADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0338841
DESCRIPTIONUS2003118592
DESCRIPTIONUS2003133939
DESCRIPTIONWO0243478
DESCRIPTIONWO2004035607
DESCRIPTIONWO8704462
DESCRIPTIONWO8901036
OPPOSITIONEP3725810
OPPOSITIONWO2007059997
OPPOSITIONWO2008145338
OPPOSITIONWO2013174509
SEARCHWO2010009794
SEARCHWO2011090005

Non-Patent Literature (NPL) Citations (51) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", Monoclonal Antibodies For Cancer Detection And Therapy, Academic Press, (19850000), pages 303 - 16-
DESCRIPTION- "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", THORPE, Monoclonal Antibodies '84: Biological And Clinical Applications, (19850000), pages 475 - 506-
DESCRIPTION- BENNY K.C., Lo Antibody Engineering, ISBN 1-58829-092-1-
DESCRIPTION- BIRD et al., Science, (19880000), vol. 242, pages 423 - 426-
DESCRIPTION- FISCHER, R. et al., Biol. Chem., (19990000), vol. 380, pages 825 - 839-
DESCRIPTION- GLENN E. MORRIS, Epitope Mapping Protocols (Methods in Molecular Biology, ISBN 089603-375-9-
DESCRIPTION- HELLSTROM et al., Antibodies For Drug Delivery'', in Controlled Drug Delivery, Marcel Dekker, Inc., (19870000), pages 623 - 53-
DESCRIPTION- HOLLIGER, P. et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 6444 - 6448-
DESCRIPTION- HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883-
DESCRIPTION- JONES, P. et al., Nature, (19860000), vol. 321, pages 522 - 525-
DESCRIPTION- KOHLERMILSTEIN, Nature, (19750000), vol. 256, page 495-
DESCRIPTION- KRAUS et al., Methods in Molecular Biology series, Recombinant antibodies for cancer therapy, ISBN 0-89603-918-8-
DESCRIPTION- "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", AMON et al., Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., (19850000), pages 243 - 56-
DESCRIPTION- MORRISON, S., Science, (19850000), vol. 229, page 1202-
DESCRIPTION- NEDDLEMANWUNSCH, J. Mol. Biol., (19700000), vol. 48, page 443-
DESCRIPTION- OLWYN M. R. WESTWOODFRANK C. HAY, "Epitope Mapping: A Practical Approach", Practical Approach Series, page 248-
DESCRIPTION- PEARSONLIPMAN, Proc. Natl Acad. Sci. USA, (19880000), vol. 85, page 2444-
DESCRIPTION- POLJAK, R. J. et al., Structure, (19940000), vol. 2, pages 1121 - 1123-
DESCRIPTION- POLLOCK et al., J. Immunol. Meth., (19990000), vol. 231, pages 147 - 157-
DESCRIPTION- QUEEN, C. et al., Proc. Natl. Acad. Sci. U. S. A., (19890000), vol. 86, pages 10029 - 10033-
DESCRIPTION- RIECHMANN, L. et al., Nature, (19980000), vol. 332, pages 323 - 327-
DESCRIPTION- ROSSI et al., Am. J. Clin. Pathol., (20050000), vol. 124, page 295-
DESCRIPTION- SCATCHARD et al., Ann N.Y. Acad. ScL, (19490000), vol. 51, page 660-
DESCRIPTION- SMITHWATERMAN, Ads App. Math., (19810000), vol. 2, page 482-
DESCRIPTION- SPIEKER-POLET et al., Proc. Natl. Acad. Sci. U.S.A., (19950000), vol. 92, page 9348-
DESCRIPTION- VERMA, R. et al., J. Immunol. Meth., (19980000), vol. 216, pages 165 - 181-
DESCRIPTION- WARD et al., Nature, (19890000), vol. 341, pages 544 - 546-
DESCRIPTION- WELSCHOFKRAUS, Recombinant antibodes for cancer therapy, ISBN 0-89603-918-8-
DESCRIPTION- ZITVOGEL L. et al., Cell, (20100000), vol. 140, pages 798 - 804-
DESCRIPTION- THORPE et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., (19820000), vol. 62, doi:10.1111/j.1600-065X.1982.tb00392.x, pages 119 - 58, XP001179872
OPPOSITION- Anonymous, "Carmustine", Wikipedia, Wikipedia, URL: https://en.wikipedia.org/w/index.php?title=Carmustine&oldid=1136256728, (20231013), XP093091542-
OPPOSITION- Anonymous, "Etoposide", Wikipedia, Wikipedia, (20231013), XP093091554-
OPPOSITION- Eichhorst S T, Müerköster S., Weigand M.A., Krammer P.H. , "The Chemotherapeutic Drug 5-Fluorouracil Induces Apoptosis in Mouse Thymocytes in Vivo via Activation of the CD95(APO-1/Fas) System", Cancer Research, (20010101), vol. 61, pages 243 - 248, XP093091618-
OPPOSITION- "P56856 · CLD18_HUMAN", UniProt, URL: https://www.uniprot.org/uniprotkb/P56856/entry#P56856-
OPPOSITION- Schuler M, "History of Changes for Study: NCT00909025 - Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer", (20100611), URL: https://clinicaltrials.gov/ct2/history/NCT00909025?A=8&B=8&C=m., (20231013), XP093091456-
OPPOSITION- Sulkes A, Smyth J, Sessa C, Dirix L Y, Vermorken J B, Kaye S, Wanders J, Franklin H, Lebail N, Verweij J, "Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial", Br Journal Cancer, (19940101), vol. 70, pages 380 - 383, XP093091440-
OPPOSITION- VELDERS M.P. et al., "The impact of antigen density and antibody affinity on antibody- dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas", British Journal of Cancer, (19980000), vol. 78, pages 478 - 483, XP009027871-
OPPOSITION- TOKUYAMA et al., "Vy982 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - Rituximab and trastuzumab", Int. J. Cancer, (20080000), vol. 122, doi:10.1002/ijc.23365, pages 2526 - 2534, XP071285149
OPPOSITION- Muñoz‐sánchez Jorge, Chánez‐cárdenas María E., "The use of cobalt chloride as a chemical hypoxia model", Journal of Applied Toxicology, WILEY HEYDEN LTD, GB, GB , (20190401), vol. 39, no. 4, doi:10.1002/jat.3749, ISSN 0260-437X, pages 556 - 570, XP093091472
OPPOSITION- OKINES A. et al., "Targeting the human EGFR family in esophagogastric cancer", Nature Re. Clinical Oncology, (20110000), vol. 8, doi:10.1038/nrclinonc.2011.45, pages 492 - 503, XP055359612
OPPOSITION- Shaulian Eitan; Karin Michael, "AP-1 in cell proliferation and survival", Oncogene, Nature Publishing Group UK, London, London , (20010430), vol. 20, no. 19, doi:10.1038/sj.onc.1204383, ISSN 0950-9232, pages 2390 - 2400, XP037732227
OPPOSITION- ROTI ROTI, "Cellular responses to hyperthermia (40-46°C): Cell killing and molecular events", Int. J. Hyperthermia, (20080200), vol. 24, no. 1, doi:10.1080/02656730701769841, pages 3 - 15, XP009167442
OPPOSITION- EICHHORST S.T. et al., "A Novel AP -1 Element in the CD 95 Ligand Promoter Is Required for Induction of Apoptosis in Hepatocellular Carcinoma Cells upon Treatment with Anticancer Drugs", Molecular and Cellular Biology, (20000000), vol. 20, doi:10.1128/MCB.20.20.7826-7837.2000, pages 7826 - 7837, XP002194897
OPPOSITION- Allum W. H., Blazeby J. M., Griffin S. M., Cunningham D., Jankowski J. A., Wong R., "Guidelines for the management of oesophageal and gastric cancer", Gut microbiota, British medical association , London, UK, UK , (20111101), vol. 60, no. 11, doi:10.1136/gut.2010.228254, ISSN 0017-5749, pages 1449 - 1472, XP093091551
OPPOSITION- Yano Koichi, Imaeda Takashi, Niimi Tomoaki, "Transcriptional activation of the human claudin-18 gene promoter through two AP-1 motifs in PMA-stimulated MKN45 gastric cancer cells", American Journal of Physiology - Gastrointestinal and Liver Physiology, American Physiological Society, US, US , (20071114), vol. 294, no. 1, doi:10.1152/ajpgi.00328.2007, ISSN 0193-1857, pages G336 - G343, XP093091614
OPPOSITION- NIWA R. et al., "Enhanced Natural Killer Cell Binding and Activation by Low-Fucose IgG1 Antibody Results in Potent Antibody-Dependent Cellular Cytotoxicity Induction at Lower Antigen Density", Clinical Cancer Research, (20050000), vol. 11, doi:10.1158/1078-0432.CCR-04-2263, pages 2327 - 2336, XP009144270
OPPOSITION- REV: SAHIN U. et al., "Claudin-18 SpliceVariant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development", Clin Cancer Res, (20080000), vol. 14, doi:10.1158/1078-0432.CCR-08-1547, pages 7624 - 7634, XP002588324
OPPOSITION- Zaniboni A., Meriggi F., "The Emerging Role of Oxaliplatin in the Treatment of Gastric Cancer", Journal of chemotherapy, SCRIT, IT, IT , (20051201), vol. 17, no. 6, doi:10.1179/joc.2005.17.6.656, ISSN 1120-009X, pages 656 - 662, XP093091622
OPPOSITION- Sastre Javier, García-Saenz Jose Angel, Díaz-Rubio Eduardo, "Chemotherapy for gastric cancer", World Journal of Gastroenterology, WJG Press, CN, CN , (20060101), vol. 12, no. 2, doi:10.3748/wjg.v12.i2.204, ISSN 1007-9327, pages 204 - 213, XP093091466
OPPOSITION- Bagnyukova Tetyana V., Serebriiskii Ilya G., Zhou Yan, Hopper-Borge Elizabeth A., Golemis Erica A., Astsaturov Igor, "Chemotherapy and signaling : How can targeted therapies supercharge cytotoxic agents?", Cancer biology & therapy, Landes Bioscience, US, US , (20101101), vol. 10, no. 9, doi:10.4161/cbt.10.9.13738, ISSN 1538-4047, pages 839 - 853, XP093091620
SEARCH- KOBUNAI TAKASHI ET AL, "Antitumour Activity of S-1 in Combination with Cetuximab on Human Gastric Cancer Cell Lines In Vivo", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, (20111101), vol. 31, no. 11, ISSN 0250-7005, pages 3691 - 3696, XP002678607 [A] 1-10 * abstract *-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents